Management of hepatitis B and C in special population

doi:10.3748/wjg.v27.i40.6861

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 40

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8299)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

525

WORD

210

HTML

4312

Figures (1-3)

308

Tables (1-3)

450

Sum=5805

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

326

Download

642

Sum=968

Publishing Process of This Article

Item

Count

Browse

516

Download

1010

Sum=1526

Oct 28, 2021 (publication date) through Dec 23, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Oct 28, 2021; 27(40): 6861-6873
Published online Oct 28, 2021. doi: 10.3748/wjg.v27.i40.6861

Full Size Figure Download Figure

Figure 2 Indications and safety of drugs in special circumstances for hepatitis B. Created with biorender.com. TAF: Tenofovir alafenamide fumarate; TDF: Tenofovir disoproxil fumarate; ETV: Entecavir.

Citation: Kulkarni AV, Duvvuru NR. Management of hepatitis B and C in special population. World J Gastroenterol 2021; 27(40): 6861-6873
URL: https://www.wjgnet.com/1007-9327/full/v27/i40/6861.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i40.6861